Highlight
In more than 113,000 ovarian cancer patients undergoing germline testing, 6.6% of those aged 70 years or older carried pathogenic or likely pathogenic variants in established ovarian cancer susceptibility genes.
Older patients were about 1.5-fold less likely to report a family history of cancer, suggesting that family-history-based referral strategies lose sensitivity with age.
BRCA1 and Lynch syndrome variants declined with age, while BRCA2 became more frequent than BRCA1 among patients aged 70 and older, and moderate-penetrance genes such as BRIP1 and PALB2 were relatively enriched.
The findings support age-inclusive genetic counseling and testing in ovarian cancer rather than restricting access based on age or family history alone.
Background
Universal or near-universal germline testing has become a central component of ovarian cancer care because inherited pathogenic variants influence treatment, prognosis, cascade testing, and opportunities for cancer prevention in relatives. Current clinical practice is strongly shaped by the high prevalence of BRCA1, BRCA2, and mismatch repair gene variants in epithelial ovarian cancer, as well as by the therapeutic relevance of homologous recombination deficiency and platinum sensitivity. Germline results may affect use of PARP inhibitors, eligibility for surveillance or preventive surgery in family members, and counseling regarding risks of breast, colorectal, endometrial, pancreatic, and other cancers depending on the gene involved.
Yet older women remain relatively underexamined in hereditary cancer literature and, in practice, may be less likely to be referred for testing. This gap has several causes. First, hereditary cancer syndromes are often conceptualized as disorders of early-onset disease. Second, referral pathways still often rely on family history, which may be incomplete, unknown, or less informative in older adults because small family size, competing mortality, adoption, sex distribution in relatives, or inaccurate recall can obscure inherited risk. Third, clinicians may incorrectly assume that germline results offer less value once a patient reaches advanced age. That assumption is increasingly difficult to justify, because results still inform systemic therapy, second-primary risk, and cascade testing for descendants and other relatives.
The study by Shachar and colleagues addresses this clinically important blind spot by examining age-stratified real-world germline testing results in a very large cohort of ovarian cancer patients, with particular focus on those aged 70 years and older. The central question is not whether hereditary risk declines with age; it does. Rather, the more useful clinical question is whether enough older patients still harbor actionable germline findings to justify broader, age-inclusive testing strategies. This analysis suggests that the answer is yes.
Study Design
This was a retrospective registry-based analysis of ovarian cancer patients who underwent germline testing through the Myriad Collaborative Research Registry between 1996 and 2024. The cohort included 113,236 patients with ovarian cancer, making this one of the largest real-world datasets assembled to examine inherited cancer susceptibility in this disease.
The primary analytic focus was age at ovarian cancer diagnosis, with special attention to patients aged 70 years or older. Investigators assessed the prevalence of pathogenic or likely pathogenic germline variants overall and within established ovarian cancer susceptibility genes. They also evaluated ancestry, family history reporting, and testing patterns across age groups.
The abstract does not provide the full gene list, but the reported results clearly include BRCA1, BRCA2, Lynch syndrome genes, BRIP1, PALB2, ATM, RAD51C, RAD51D, and PMS2. The main comparator was patients younger than 70 years. The study appears descriptive and hypothesis-generating rather than interventional; it does not test clinical outcomes after a management change, but rather examines the prevalence and distribution of inherited risk markers that may influence counseling and care.
Because the analysis is based on a commercial testing registry, it reflects real-world referral and testing behavior over a long period. That is a major strength for scale and clinical relevance, although it also introduces the usual concerns about referral bias, changing panel composition over time, variable ascertainment of family history, and limited access to pathology-level variables within an abstract.
Key Findings
Overall burden of pathogenic variants remained clinically meaningful
Among all 113,236 ovarian cancer patients, 14,513 patients, or 12.8%, harbored a pathogenic or likely pathogenic germline variant. Of these, 13,049 patients, or 11.5% of the overall cohort, had variants in established ovarian cancer susceptibility genes. This overall prevalence is broadly consistent with prior literature showing that a meaningful minority of unselected ovarian cancer patients carry inherited susceptibility variants, especially in BRCA1 and BRCA2.
The clinically important point is that prevalence declined with age but did not disappear. Patients aged 70 years or older represented 20% of the cohort, totaling 22,593 individuals. In this older group, 6.6% carried a pathogenic or likely pathogenic variant in established ovarian cancer susceptibility genes, compared with 12.8% among those younger than 70 years, a statistically significant difference with p < 0.01.
From a counseling standpoint, a 6.6% prevalence is not trivial. In practical terms, this means roughly 1 in 15 ovarian cancer patients aged 70 or older had an actionable inherited finding in a recognized susceptibility gene. That yield exceeds many thresholds clinicians would consider sufficient to justify routine testing, especially when the information can affect both the patient and at-risk relatives.
Gene distribution shifted with age
The age-related decline was not uniform across genes. BRCA1, BRCA2, and Lynch syndrome variants all became less common with increasing age at diagnosis. This aligns with the established biology of high-penetrance hereditary ovarian cancer syndromes, which tend to present earlier than sporadic disease.
However, the pattern within BRCA genes is notable. Among patients aged 70 years or older, BRCA2 exceeded BRCA1. This shift is biologically plausible and clinically relevant. BRCA1-associated ovarian cancer often presents earlier, whereas BRCA2-related risk tends to occur later and may remain underrecognized in older patients if clinicians assume that advanced age makes hereditary etiology unlikely.
The study also found relative enrichment of moderate-penetrance genes such as BRIP1 and PALB2 in older patients. Meanwhile, ATM and RAD51C/RAD51D remained relatively stable across age groups. These observations matter because contemporary hereditary cancer counseling cannot focus solely on BRCA1 and BRCA2. Multi-gene panel testing increasingly identifies variants with more nuanced age-specific penetrance and less dramatic family-history signals. In older adults, this may be exactly where family-history-based selection performs worst.
Another interesting finding is the apparent frequency of PMS2 variants, reported as more common than previously described, though also declining with age, with p = 0.03. PMS2 has often been considered a lower-penetrance Lynch syndrome gene with more variable phenotype expression and more challenging interpretation in historical datasets. If PMS2 is indeed more prevalent in ovarian cancer testing populations than previously appreciated, that has implications for counseling regarding colorectal and endometrial cancer risk in relatives and for how clinicians think about Lynch syndrome architecture in ovarian cancer.
Family history was less informative in the oldest patients
Perhaps the most practice-changing result is not the age decline in variant prevalence itself, but the marked reduction in reported family history among older patients. Patients aged 70 years or older were 1.5-fold less likely to report a cancer family history. This finding directly challenges referral models that rely heavily on pedigree triggers.
There are several reasons family history may be less sensitive in older adults. Families may be smaller, records incomplete, or relatives may have died before developing recognizable cancers. Maternal and paternal transmission may be obscured by sex-limited cancer phenotypes. Prior generations may not have had access to precise pathology diagnosis. Cultural, linguistic, or adoption-related factors may further reduce reporting accuracy. Importantly, none of these factors reduces the biological relevance of a germline variant; they merely reduce the visibility of hereditary risk when clinicians screen using family history alone.
In effect, the study suggests that older ovarian cancer patients are doubly disadvantaged by traditional triage: they have a lower average probability of a positive result than younger patients, but they are also less likely to display the family-history cues that would prompt testing in the first place. The consequence is potentially avoidable underdiagnosis of hereditary cancer syndromes in exactly the population that many clinicians may already underserve.
Why the findings are clinically actionable
The abstract concludes that many older patients harbor actionable variants despite lacking family history that would otherwise prompt risk-reducing interventions. “Actionable” should be understood broadly. For the patient, germline findings may influence treatment selection, genetic counseling, and consideration of associated cancer risks. For relatives, they can trigger cascade testing and, where appropriate, enhanced surveillance or prophylactic surgery.
Even when the index patient is in her seventies or older, the downstream benefit to family members can be substantial. Children, grandchildren, siblings, nieces, and nephews may still be within windows where preventive action meaningfully reduces morbidity and mortality. In this sense, age does not diminish the public health value of testing; it may only change the balance between direct and indirect benefit.
Clinical Interpretation
These data reinforce the rationale for offering germline testing to essentially all patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of age at diagnosis or family history. This position is already supported by major guidelines, including the National Comprehensive Cancer Network, which has long recommended germline testing for all patients with epithelial ovarian cancer. The present study does not overturn that framework; rather, it strengthens it by addressing a population that is often tacitly marginalized in real-world implementation.
For gynecologic oncologists, medical oncologists, genetic counselors, internists, and primary care clinicians caring for older adults, the practical lesson is straightforward: do not use advanced age as a reason to forgo referral. Nor should absent or limited family history reassure clinicians that inherited susceptibility is unlikely enough to ignore. If anything, this study suggests that absence of reported family history is a weaker negative predictor in older patients than in younger ones.
The shift toward relatively greater representation of BRCA2, BRIP1, and PALB2 in older age also argues for comprehensive panel testing rather than narrow, syndrome-driven testing based only on classic early-onset patterns. Contemporary hereditary cancer practice increasingly depends on multi-gene panels because gene-specific penetrance, phenotype breadth, and therapeutic implications vary, and because ovarian cancer can be the presenting event for several inherited syndromes.
Strengths and Limitations
The most obvious strength is scale. A cohort of more than 113,000 ovarian cancer patients provides unusually robust precision for age-stratified estimates and for analysis of less common susceptibility genes. The real-world nature of the registry also improves applicability to routine practice compared with highly selected academic cohorts.
However, several limitations should temper interpretation. First, this was a retrospective analysis of patients who underwent testing, not a population-based study of all ovarian cancer cases. Referral bias is likely; tested patients may differ systematically from untested patients in ancestry, access to specialty care, socioeconomic status, or clinician suspicion of hereditary cancer. Second, testing panels evolved over the long study period from 1996 to 2024, which could alter apparent prevalence of specific genes. Third, family history reporting in commercial testing databases may be incomplete and heterogeneous. Fourth, the abstract does not specify ovarian cancer histology, stage, or the proportion with epithelial versus non-epithelial tumors, details that could affect gene prevalence. Finally, because outcome data are not provided, the study cannot directly quantify how often testing altered therapy, surveillance, or cascade testing uptake.
Even with these caveats, the core message is unlikely to be overturned: clinically meaningful inherited risk persists in ovarian cancer well beyond age 70, and family history alone is an insufficient gatekeeper.
Implications for Practice and Policy
At the clinical level, the study supports universal or near-universal germline testing pathways embedded into ovarian cancer care, including for older adults. Testing should ideally be offered early, at diagnosis or first oncology consultation, and not deferred because of assumptions about age, comorbidity, or family structure.
At the systems level, the findings support streamlined models such as oncologist-led mainstreaming with genetics referral for positive, uncertain, or complex results. These models may be particularly useful for older patients, who can face logistical barriers to separate genetics appointments. Educational efforts should also address age bias in testing referrals and emphasize that the value of testing extends beyond the index patient.
For counseling, clinicians should explain that although the chance of finding an inherited variant is lower after age 70 than at younger ages, it remains high enough to matter. A concise way to frame the discussion is that age changes probability, not relevance. A negative family history should not be treated as a reason to decline testing, especially in ovarian cancer, where guideline-based testing is already broad.
Conclusion
Shachar and colleagues provide persuasive large-scale evidence that ovarian cancer patients aged 70 years and older still carry clinically actionable germline variants at a meaningful rate. Although prevalence is lower than in younger patients, approximately 6.6% of older patients had pathogenic or likely pathogenic variants in established ovarian cancer susceptibility genes, and they were substantially less likely to report a family history of cancer. The implication is clear: family-history-based approaches become less sensitive with age and risk missing patients who could benefit from genetic information. For clinicians and health systems, the appropriate response is not to narrow testing in older adults, but to ensure that age-inclusive, guideline-concordant germline testing is consistently offered.
Funding and ClinicalTrials.gov
The abstract describes a retrospective analysis of the Myriad Collaborative Research Registry and does not report a ClinicalTrials.gov registration number. Specific study funding details are not provided in the abstract and should be confirmed from the full text.
References
1. Shachar E, Rotkop G, Haas R, Frankenthal R, Kamara D, Demirjian M, Kwan L, Cummings S, Roscow B, Salani R, Spellman PT, Karlan B, Chase DM. Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventy. Gynecologic Oncology. 2026;209:77-87. PMID: 42114202.
2. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. Current NCCN Clinical Practice Guidelines in Oncology. Access should be verified through the NCCN guideline portal.
3. National Comprehensive Cancer Network. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Current NCCN Clinical Practice Guidelines in Oncology. Access should be verified through the NCCN guideline portal.
4. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, King MC, Swisher EM, Birrer MJ. Inherited mutations in women with ovarian carcinoma. JAMA Oncology. 2016;2(4):482-490.
5. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks GD, Nicosia SV, Cantor A, Sutphen R. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816.
